Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B17 | O75795 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4014378 | 0.78 | — | — | |
| SCHEMBL4017056 | 0.66 | — | — | |
| SCHEMBL20038895 | 0.65 | KDM4E (0.39) | UGT2B17 | |
| SCHEMBL9883861 | 0.65 | UGT2B17 (0.37) | UGT2B17 | |
| SCHEMBL10445894 | 0.65 | UGT2B17 (0.37) | UGT2B17 | |
| SCHEMBL14394191 | 0.65 | — | — | |
| SCHEMBL4016494 | 0.64 | ALDH1A1 (0.35) | — | |
| SCHEMBL26667368 | 0.63 | — | — | |
| SCHEMBL29906669 | 0.62 | UGT2B17 (0.32) | UGT2B17 | |
| SCHEMBL1786084 | 0.62 | UGT2B17 (0.32) | UGT2B17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7598417-B2 | Analgesics; muscular disorders; diarrhea | ALLERGAN, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ALLERGAN, INC. | 2008-10-16 | — | — | US | disclosed |
| US-6384045-B1 | TREATMENT OF ALZHEIMER'S DISEASE AND ANTICANCER AGENTS | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION | 2002-05-07 | — | — | US | disclosed |
| WO-1998039010-A1 | TRICYCLIC AND TETRACYCLIC PYRONES | KANSAS STATE UNIVERSITY RESEARCH FOUNDATION (US) | 1998-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255239-A1 | SUBSTITUTED FLUOROETHYL UREAS AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2A, ADRA2C | UGT2B17 1140/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.